Kejian Lu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Kejian Lu has a total of 43 co-authors. Here are the top co-authors by number of shared publications:
- Yanjuan Huang
Department of Anesthesiology The Third Affiliated Hospital of Guangxi Medical University Nanning Guangxi China
5 shared publications Shucong Liang
Department of Anesthesiology The Third Affiliated Hospital of Guangxi Medical University Nanning Guangxi China
4 shared publicationsHuageng Huang
Department of Anesthesiology, The Third Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi, China
2 shared publicationsLijuan Bai
Department of Anesthesiology The Third Affiliated Hospital of Guangxi Medical University Nanning Guangxi China
2 shared publicationsNing Wei
Department of Anesthesiology, Hechi Third People’s Hospital, Hechi, Guangxi, China
2 shared publicationsYanxia Wei
Department of Anesthesiology The Third Affiliated Hospital of Guangxi Medical University Nanning Guangxi China
2 shared publications
Latest Publications
- Open Access
- 30 June 2026
- Published by Wiley in Journal of the American Geriatrics Society
- Vol. 74 (9) , 2564-2572
Perioperative Transfusion Trigger Score Versus Restrictive Transfusion in Older Non‐Cardiac Surgery Patients: A Multicenter Randomized Controlled Trial
Background: Restrictive transfusion (Hb < 7 g/dL) is recommended for most perioperative patients, but the optimal threshold for those with cardiovascular disease or Hb 7–10 g/dL remains uncertain. The Perioperative Transfusion Trigger Score (POTTS), which integrates adrenaline requirement, FiO 2 , temperature, and angina history, may standardize decisions and safely reduce transfusions in older non‐cardiac surgery patients. Methods: This multicenter RCT in two Chinese hospitals randomized patients ≥ 60 years undergoing non‐cardiac surgery 1:1 to POTTS or control. POTTS = 6 plus points for adrenaline, FiO 2 (to maintain SpO 2 ≥ 95%), core temperature, and angina; transfusion when Hb < POTTS. Control followed 2012 AABB guideline (Hb < 7 always transfuse; > 10 not; 7–10 physician discretion). Primary outcome: proportion receiving allogeneic RBC transfusion during perioperative period (ITT population). Results: 253 patients (mean age 72.3 years; 67.6% women) were randomized (May 2023‐Sept 2025). Baseline Hb similar (median 9.60 vs. 9.50 g/dL). In ITT, transfusion required in 24.00% (30/125) of POTTS vs. 35.94% (46/128) of control ( p = 0.038). Transfusion volume did not differ significantly (median 2.50 vs. 3.00 units, p = 0.520). Overall complication rates: 12.80% vs. 8.59% ( p = 0.279); one death in control group (0.85%). No significant differences in specific complications. Conclusion: In patients ≥ 60 years undergoing non‐cardiac surgery, POTTS‐guided transfusion significantly reduced the proportion of patients transfused without increasing complications. Trial Registration: This study was registered at http://www.chictr.org.cn (#ChiCTR2300071739)
- 30 June 2026
- Published by Wiley in Journal of the American Geriatrics Society
- Vol. 74 (9) , 2564-2572
Open AccessPerioperative Transfusion Trigger Score Versus Restrictive Transfusion in Older Non‐Cardiac Surgery Patients: A Multicenter Randomized Controlled Trial
Background: Restrictive transfusion (Hb < 7 g/dL) is recommended for most perioperative patients, but the optimal threshold for those with cardiovascular disease or Hb 7–10 g/dL remains uncertain. The Perioperative Transfusion Trigger Score (POTTS), which integrates adrenaline requirement, FiO 2 , temperature, and angina history, may standardize decisions and safely reduce transfusions in older non‐cardiac surgery patients. Methods: This multicenter RCT in two Chinese hospitals randomized patients ≥ 60 years undergoing non‐cardiac surgery 1:1 to POTTS or control. POTTS = 6 plus points for adrenaline, FiO 2 (to maintain SpO 2 ≥ 95%), core temperature, and angina; transfusion when Hb < POTTS. Control followed 2012 AABB guideline (Hb < 7 always transfuse; > 10 not; 7–10 physician discretion). Primary outcome: proportion receiving allogeneic RBC transfusion during perioperative period (ITT population). Results: 253 patients (mean age 72.3 years; 67.6% women) were randomized (May 2023‐Sept 2025). Baseline Hb similar (median 9.60 vs. 9.50 g/dL). In ITT, transfusion required in 24.00% (30/125) of POTTS vs. 35.94% (46/128) of control ( p = 0.038). Transfusion volume did not differ significantly (median 2.50 vs. 3.00 units, p = 0.520). Overall complication rates: 12.80% vs. 8.59% ( p = 0.279); one death in control group (0.85%). No significant differences in specific complications. Conclusion: In patients ≥ 60 years undergoing non‐cardiac surgery, POTTS‐guided transfusion significantly reduced the proportion of patients transfused without increasing complications. Trial Registration: This study was registered at http://www.chictr.org.cn (#ChiCTR2300071739)
- Open Access
Liposomal bupivacaine versus ropivacaine perianal infiltration for postoperative analgesia of haemorrhoidectomy: a multicentre, randomised controlled trial
Objectives To evaluate whether liposomal bupivacaine provides superior postoperative analgesia compared with ropivacaine following haemorrhoidectomy, reduces the need for rescue analgesics in patients with mixed haemorrhoids and maintains a comparable safety profile. Design Prospective, randomised controlled multicentre trial. Setting Three grade 3A general hospitals in Guangxi, China, conducted between September 2023 and July 2024. Participants Eligible patients were aged 18–75 years undergoing elective external dissection and internal ligation for mixed haemorrhoids (grade III and IV mixed haemorrhoids). Key exclusion criteria were severe systemic diseases, history of substance abuse or known allergies to local anaesthetics. A total of 264 patients (male, n=162; mean age, 43.1±12.2 years) were enrolled and completed the study, with 132 randomised to each group. Interventions Patients received either ropivacaine (100 mg in 20 mL) or liposomal bupivacaine (226 mg in 20 mL) through local infiltration at the end of surgery. Primary and secondary outcome measures The primary outcomes were the resting numerical rating scale (NRS) pain scores (0–10) at postoperative 1, 5, 7, 9, 11, 24, 36, 48 and 72 hours. The secondary outcomes included the following: (1) exercise NRS pain scores at the same time points; (2) time to first ambulation, ambulation NRS pain scores on postoperative days 1, 2 and 3 and the proportion of patients having ambulation NRS pain scores ≥4; (3) defecation NRS pain scores and the proportion of of patients having score ≥4; (4) the time to the first administration of rescue analgesics and proportion of patients requiring rescue analgesics; (5) proportion of pain-free patients (NRS pain scores ≤1) 0–24, 24–72 and 0–72 hour after surgery; (6) incision assessments on postoperative days 1, 3 and 7 and postoperative adverse events (AEs); and (7) patients’ and researchers’ satisfaction with pain management. Results Resting NRS pain scores were significantly lower in the liposomal bupivacaine group at all time points (median, 0–2.0 vs 2.0–4.0 for ropivacaine, pConclusions Perianal infiltration of liposomal bupivacaine significantly alleviates postoperative resting and exercise pain in patients undergoing surgery for mixed haemorrhoids, enhances comfort during ambulation and defecation, reduces the need for additional analgesics and demonstrates a safety profile comparable to that of ropivacaine. Trial registration chictr.org.cn # ChiCTR2300075276.
Open AccessLiposomal bupivacaine versus ropivacaine perianal infiltration for postoperative analgesia of haemorrhoidectomy: a multicentre, randomised controlled trial
Objectives To evaluate whether liposomal bupivacaine provides superior postoperative analgesia compared with ropivacaine following haemorrhoidectomy, reduces the need for rescue analgesics in patients with mixed haemorrhoids and maintains a comparable safety profile. Design Prospective, randomised controlled multicentre trial. Setting Three grade 3A general hospitals in Guangxi, China, conducted between September 2023 and July 2024. Participants Eligible patients were aged 18–75 years undergoing elective external dissection and internal ligation for mixed haemorrhoids (grade III and IV mixed haemorrhoids). Key exclusion criteria were severe systemic diseases, history of substance abuse or known allergies to local anaesthetics. A total of 264 patients (male, n=162; mean age, 43.1±12.2 years) were enrolled and completed the study, with 132 randomised to each group. Interventions Patients received either ropivacaine (100 mg in 20 mL) or liposomal bupivacaine (226 mg in 20 mL) through local infiltration at the end of surgery. Primary and secondary outcome measures The primary outcomes were the resting numerical rating scale (NRS) pain scores (0–10) at postoperative 1, 5, 7, 9, 11, 24, 36, 48 and 72 hours. The secondary outcomes included the following: (1) exercise NRS pain scores at the same time points; (2) time to first ambulation, ambulation NRS pain scores on postoperative days 1, 2 and 3 and the proportion of patients having ambulation NRS pain scores ≥4; (3) defecation NRS pain scores and the proportion of of patients having score ≥4; (4) the time to the first administration of rescue analgesics and proportion of patients requiring rescue analgesics; (5) proportion of pain-free patients (NRS pain scores ≤1) 0–24, 24–72 and 0–72 hour after surgery; (6) incision assessments on postoperative days 1, 3 and 7 and postoperative adverse events (AEs); and (7) patients’ and researchers’ satisfaction with pain management. Results Resting NRS pain scores were significantly lower in the liposomal bupivacaine group at all time points (median, 0–2.0 vs 2.0–4.0 for ropivacaine, pConclusions Perianal infiltration of liposomal bupivacaine significantly alleviates postoperative resting and exercise pain in patients undergoing surgery for mixed haemorrhoids, enhances comfort during ambulation and defecation, reduces the need for additional analgesics and demonstrates a safety profile comparable to that of ropivacaine. Trial registration chictr.org.cn # ChiCTR2300075276.
- Open Access
- 1 April 2025
- Published by Taylor & Francis in Journal of Inflammation Research
- Vol. ume 18, 5427-5445
Identification of Hub Genes for Dexmedetomidine Alleviation of Limb Ischemia-Reperfusion-Induced Lung Injury in Rats by Transcriptomic
Background: Limb ischemia-reperfusion (LIR), a prevalent clinical condition, frequently precipitates acute lung injury (ALI). Dexmedetomidine (DEX), a selective alpha2-adrenergic receptor agonist, mitigates LIR-induced ALI. However, its underlying mechanisms remain incompletely elucidated. This study aimed to identify hub genes implicated in DEX-mediated protection against LIR-ALI in rats. Methods: Sprague-Dawley rats were allocated into five groups (n = 3 per group): Sham (femoral artery exposure without occlusion), LIR, LIR + DEX, LIR + Inhibitor, and LIR + DEX + Inhibitor. LIR was induced by clamping the femoral arteries for 3 hours, followed by reperfusion. DEX (50 μg/kg) or Atipamezole (alpha2-receptor inhibitor, 250 μg/kg) was administered prior to ischemia. Lung injury was evaluated via hematoxylin-eosin staining, wet/dry ratio assessment, and quantification of IL-1beta, TNF-alpha, malondialdehyde (MDA), and superoxide dismutase (SOD) levels. RNA sequencing was performed to identify differentially expressed genes (DEGs), followed by functional enrichment analysis, protein-protein interaction (PPI) network construction, and hub gene identification. Gene-gene interaction (GGI) networks were established. Polymerase chain reaction (PCR) and enzyme linked immunosorbent assay (ELISA) validation was conducted. Results: LIR induced severe lung injury and inflammation, both of which were attenuated by DEX pretreatment. RNA sequencing identified 2,302 DEGs1, 471 DEGs2, 340 DEGs3, and 1,407 DEGs4. After intersection and subtraction analyses, 255 DEX-associated DEGs (DEGs-Dex) and 290 inhibitor-associated DEGs (DEGs-In) were identified, with enrichment in Wnt/PI3K-Akt signaling (DEX) and glycerolipid/butanoate metabolism (In). Nine Hub-Dex genes and four Hub-In genes were identified, among which Selp and Tars1 exhibited a strong positive correlation (correlation = 0.55, P < 0.05). Six hub genes (Tars1, Atf4, Ep300, Sphk1, AABR07051376.1, and Mmp9) were validated. Conclusion: Six hub genes associated with DEX-mediated protection against LIR-ALI were identified, providing mechanistic insights and potential therapeutic targets for intervention.
- 1 April 2025
- Published by Taylor & Francis in Journal of Inflammation Research
- Vol. ume 18, 5427-5445
Open AccessIdentification of Hub Genes for Dexmedetomidine Alleviation of Limb Ischemia-Reperfusion-Induced Lung Injury in Rats by Transcriptomic
Background: Limb ischemia-reperfusion (LIR), a prevalent clinical condition, frequently precipitates acute lung injury (ALI). Dexmedetomidine (DEX), a selective alpha2-adrenergic receptor agonist, mitigates LIR-induced ALI. However, its underlying mechanisms remain incompletely elucidated. This study aimed to identify hub genes implicated in DEX-mediated protection against LIR-ALI in rats. Methods: Sprague-Dawley rats were allocated into five groups (n = 3 per group): Sham (femoral artery exposure without occlusion), LIR, LIR + DEX, LIR + Inhibitor, and LIR + DEX + Inhibitor. LIR was induced by clamping the femoral arteries for 3 hours, followed by reperfusion. DEX (50 μg/kg) or Atipamezole (alpha2-receptor inhibitor, 250 μg/kg) was administered prior to ischemia. Lung injury was evaluated via hematoxylin-eosin staining, wet/dry ratio assessment, and quantification of IL-1beta, TNF-alpha, malondialdehyde (MDA), and superoxide dismutase (SOD) levels. RNA sequencing was performed to identify differentially expressed genes (DEGs), followed by functional enrichment analysis, protein-protein interaction (PPI) network construction, and hub gene identification. Gene-gene interaction (GGI) networks were established. Polymerase chain reaction (PCR) and enzyme linked immunosorbent assay (ELISA) validation was conducted. Results: LIR induced severe lung injury and inflammation, both of which were attenuated by DEX pretreatment. RNA sequencing identified 2,302 DEGs1, 471 DEGs2, 340 DEGs3, and 1,407 DEGs4. After intersection and subtraction analyses, 255 DEX-associated DEGs (DEGs-Dex) and 290 inhibitor-associated DEGs (DEGs-In) were identified, with enrichment in Wnt/PI3K-Akt signaling (DEX) and glycerolipid/butanoate metabolism (In). Nine Hub-Dex genes and four Hub-In genes were identified, among which Selp and Tars1 exhibited a strong positive correlation (correlation = 0.55, P < 0.05). Six hub genes (Tars1, Atf4, Ep300, Sphk1, AABR07051376.1, and Mmp9) were validated. Conclusion: Six hub genes associated with DEX-mediated protection against LIR-ALI were identified, providing mechanistic insights and potential therapeutic targets for intervention.
- Top Cited PapersOpen Access
- 5 November 2022
- Published by Wiley in Journal of Clinical Pharmacy and Therapeutics
- Vol. 47 (12) , 2230-2236
Remimazolam versus propofol for deep sedation/anaesthesia in upper gastrointestinal endoscopy in elderly patients: A multicenter, randomized controlled trial
Propofol is the most commonly used sedative in gastrointestinal endoscopic procedures, but is associated with cardiorespiratory suppression, particularly in elderly patients. Remimazolam is a new short‐acting GABA(A) receptor agonist with minimal impact on cardiorespiratory suppression, and may be a viable alternative in elderly patients undergoing endoscopic procedures. This multicenter, randomized controlled trial was conducted between September 2020 and September 2021. Elderly patients (65–85 years of age) scheduled to undergo upper gastrointestinal endoscopy were randomized in 1:1 ratio to receive remimazolam tosilate (300 mg/h) or propofol (3 g/h) in addition to 50‐μg fentanyl, until the Modified Observer's Assessment of Alertness/Sedation Scale (MOAA/S) reached ≤1. MOAA/S was maintained at 0 or 1 throughout the procedure using 2.5 mg remimazolam or 0.5 mg/kg propofol boluses in the two groups, respectively. The primary outcome was the rate of hypotension (defined as systolic blood pressure at ≤90 mmHg or > 30% decline vs. the baseline). Bradycardia was defined as heart rate ≤50 per minute; respiratory depression was defined as respiratory rate 2 < 90%. A total of 400 patients (161 men and 239 women; 70.4 ± 4.6 years of age) were enrolled (200 patients per group). Average body mass index was 22.2 ± 2.4 kg/m2. The rate of hypotension was 36.5% in the remimazolam group and 69.6% in the propofol group (p < 0.001). The remimazolam group also had a lower rate of bradycardia (1.5% vs. 8.5%, p < 0.001), respiratory depression (4.5% vs. 10.0%, p < 0.05) and pain at the injection site (0% vs. 12.0%, p < 0.001). Remimazolam was associated with a lower rate of hypotension in elderly patients undergoing upper gastrointestinal endoscopy under deep sedation/anaesthesia than propofol.
- 5 November 2022
- Published by Wiley in Journal of Clinical Pharmacy and Therapeutics
- Vol. 47 (12) , 2230-2236
Top Cited PapersOpen AccessRemimazolam versus propofol for deep sedation/anaesthesia in upper gastrointestinal endoscopy in elderly patients: A multicenter, randomized controlled trial
Propofol is the most commonly used sedative in gastrointestinal endoscopic procedures, but is associated with cardiorespiratory suppression, particularly in elderly patients. Remimazolam is a new short‐acting GABA(A) receptor agonist with minimal impact on cardiorespiratory suppression, and may be a viable alternative in elderly patients undergoing endoscopic procedures. This multicenter, randomized controlled trial was conducted between September 2020 and September 2021. Elderly patients (65–85 years of age) scheduled to undergo upper gastrointestinal endoscopy were randomized in 1:1 ratio to receive remimazolam tosilate (300 mg/h) or propofol (3 g/h) in addition to 50‐μg fentanyl, until the Modified Observer's Assessment of Alertness/Sedation Scale (MOAA/S) reached ≤1. MOAA/S was maintained at 0 or 1 throughout the procedure using 2.5 mg remimazolam or 0.5 mg/kg propofol boluses in the two groups, respectively. The primary outcome was the rate of hypotension (defined as systolic blood pressure at ≤90 mmHg or > 30% decline vs. the baseline). Bradycardia was defined as heart rate ≤50 per minute; respiratory depression was defined as respiratory rate 2 < 90%. A total of 400 patients (161 men and 239 women; 70.4 ± 4.6 years of age) were enrolled (200 patients per group). Average body mass index was 22.2 ± 2.4 kg/m2. The rate of hypotension was 36.5% in the remimazolam group and 69.6% in the propofol group (p < 0.001). The remimazolam group also had a lower rate of bradycardia (1.5% vs. 8.5%, p < 0.001), respiratory depression (4.5% vs. 10.0%, p < 0.05) and pain at the injection site (0% vs. 12.0%, p < 0.001). Remimazolam was associated with a lower rate of hypotension in elderly patients undergoing upper gastrointestinal endoscopy under deep sedation/anaesthesia than propofol.
- Open Access
- 24 May 2022
- Published by Wiley in Transfusion Medicine
- Vol. 32 (5) , 375-382
A physiology‐based trigger score to guide perioperative transfusion of allogeneic red blood cells: A multicentre randomised controlled trial
Background: Restrictive blood transfusion is recommended by major guidelines for perioperative management, but requires objective assessment at 7–10 g/dl haemoglobin (Hb). A scoring system that considers the physiological needs of the heart may simply the practice and reduce transfusion.Methods: Patients (14–65 years of age) undergoing non‐cardiac surgery were randomised at a 1:1 ratio to a control group versus a Perioperative Transfusion Trigger Score (POTTS) group. POTTS (maximum of 10) was calculated as 6 plus the following: adrenaline infusion rate (0 for no infusion, 1 for ≤0.05 μg·kg−1·min−1, and 2 for higher rate), FiO2 to keep SpO2 at ≥95% (0 for ≤35%, 1 for 36%–50%, and 2 for higher), core temperature (0 for p = 0.036). Lower rate of allogeneic RBCs transfusion in the POTTS group was also evident in the per‐protocol analysis (42.8% vs. 35.5%, p = 0.030). Transfusion volume was 4.0 (2.0, 6.0) and 3.5 (2.0, 5.5) units (200 ml/unit) in the control and POTTS groups, respectively (p = 0.25). The rate of severe postoperative complications (Clavien‐Dindo grade IIIa and higher) was 3.9% in the control group versus 1.2% in the POTTS group (p = 0.010).Conclusion: Transfusion of allogeneic RBCs based on the POTTS was safe and reduced the transfusion requirement in patients undergoing non‐cardiac surgery.
- 24 May 2022
- Published by Wiley in Transfusion Medicine
- Vol. 32 (5) , 375-382
Open AccessA physiology‐based trigger score to guide perioperative transfusion of allogeneic red blood cells: A multicentre randomised controlled trial
Background: Restrictive blood transfusion is recommended by major guidelines for perioperative management, but requires objective assessment at 7–10 g/dl haemoglobin (Hb). A scoring system that considers the physiological needs of the heart may simply the practice and reduce transfusion.Methods: Patients (14–65 years of age) undergoing non‐cardiac surgery were randomised at a 1:1 ratio to a control group versus a Perioperative Transfusion Trigger Score (POTTS) group. POTTS (maximum of 10) was calculated as 6 plus the following: adrenaline infusion rate (0 for no infusion, 1 for ≤0.05 μg·kg−1·min−1, and 2 for higher rate), FiO2 to keep SpO2 at ≥95% (0 for ≤35%, 1 for 36%–50%, and 2 for higher), core temperature (0 for p = 0.036). Lower rate of allogeneic RBCs transfusion in the POTTS group was also evident in the per‐protocol analysis (42.8% vs. 35.5%, p = 0.030). Transfusion volume was 4.0 (2.0, 6.0) and 3.5 (2.0, 5.5) units (200 ml/unit) in the control and POTTS groups, respectively (p = 0.25). The rate of severe postoperative complications (Clavien‐Dindo grade IIIa and higher) was 3.9% in the control group versus 1.2% in the POTTS group (p = 0.010).Conclusion: Transfusion of allogeneic RBCs based on the POTTS was safe and reduced the transfusion requirement in patients undergoing non‐cardiac surgery.